Brian Lockhart
Research Subjects
Research Interests
Brian Lockhart has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Pierre Lestage
Servier Research Institute, Division of Cerebral Pathology, 125, Chemin de ronde, 78290 Croissy-sur-Seine, France
3 shared publicationsAnita Roger
Servier, Division of Cerebral Pathology, 125, Chemin de ronde, 78290 Croissy-sur-Seine, France
2 shared publicationsNorbert Bonhomme
Servier, Division of Cerebral Pathology, 125, Chemin de ronde, 78290 Croissy-sur-Seine, France
2 shared publicationsA Roger
1 shared publication- Bernard Walther
Pharmacokinetic and Metabolism Centre, Technologie Servier, 27 rue E. Vignat, 45000 Orleans, France
1 shared publication Gilbert Dorey
1 shared publication
Latest Publications
- Open Access
- 15 April 2009
- Published by EDP Sciences in médecine/sciences
- Vol. 25 (4) , 423-430
Les biomarqueurs : « Found in translation »
Despite continued increase in global Pharma R & D expenditure, the number of innovative drugs obtaining market approval has declined since 1994. The pharmaceutical industry is now entering a crucial juncture where increasing rates of attrition in clinical drug development as well as increasing development timelines are impacted by external factors such as intense regulatory pricing and safety pressures, increasing sales erosion due to generics, as well as exponential increases in the costs of bringing a drug to market. Despite these difficulties, numerous opportunities exist such as multiple unmet medical needs, the increasing incidence of certain diseases such as Alzheimer's disease, cancer, diabetes and obesity due to demographic changes, as well as the emergence of evolving markets such as China, India, and Eastern Europe. Consequently, Pharma is now responding to this challenge by improving both the productivity and the innovation in its drug discovery and development pipelines. In this regard, the advent of new technologies and expertise such as genomics, proteomics, structural biology, and molecular informatics in an integrated systems biology approach also provides a powerful opportunity for Pharma to address some of these difficulties. The key features behind this new strategy imply a discovery process based on an improved understanding of the molecular mechanism of diseases and drugs, translational research that places the patient at the center of the research process, and the application of biomarkers throughout the discovery and development phases. Moreover, new paradigms are required to improve target validation and develop more predictive cellular and animal models of human pathologies, a greater capacity in informatics-based analysis, and, consequently, a greater access to the vast sources of accumulating biological data and its integrated analysis. In the present review, we will address some of these issues and in particular emphasize how the application of biomarkers could potentially lead to improved productivity, quality, and innovation in drug discovery and ultimately better and safer medicines with improved therapeutic efficacy in specific pathologies for targeted patients.
- 15 April 2009
- Published by EDP Sciences in médecine/sciences
- Vol. 25 (4) , 423-430
Open AccessLes biomarqueurs : « Found in translation »
Despite continued increase in global Pharma R & D expenditure, the number of innovative drugs obtaining market approval has declined since 1994. The pharmaceutical industry is now entering a crucial juncture where increasing rates of attrition in clinical drug development as well as increasing development timelines are impacted by external factors such as intense regulatory pricing and safety pressures, increasing sales erosion due to generics, as well as exponential increases in the costs of bringing a drug to market. Despite these difficulties, numerous opportunities exist such as multiple unmet medical needs, the increasing incidence of certain diseases such as Alzheimer's disease, cancer, diabetes and obesity due to demographic changes, as well as the emergence of evolving markets such as China, India, and Eastern Europe. Consequently, Pharma is now responding to this challenge by improving both the productivity and the innovation in its drug discovery and development pipelines. In this regard, the advent of new technologies and expertise such as genomics, proteomics, structural biology, and molecular informatics in an integrated systems biology approach also provides a powerful opportunity for Pharma to address some of these difficulties. The key features behind this new strategy imply a discovery process based on an improved understanding of the molecular mechanism of diseases and drugs, translational research that places the patient at the center of the research process, and the application of biomarkers throughout the discovery and development phases. Moreover, new paradigms are required to improve target validation and develop more predictive cellular and animal models of human pathologies, a greater capacity in informatics-based analysis, and, consequently, a greater access to the vast sources of accumulating biological data and its integrated analysis. In the present review, we will address some of these issues and in particular emphasize how the application of biomarkers could potentially lead to improved productivity, quality, and innovation in drug discovery and ultimately better and safer medicines with improved therapeutic efficacy in specific pathologies for targeted patients.
- 1 April 2007
- Published by Elsevier in European Journal of Pharmacology
- Vol. 561 (1-3) , 23-31
S18986: A positive modulator of AMPA-receptors enhances (S)-AMPA-mediated BDNF mRNA and protein expression in rat primary cortical neuronal cultures
- 1 April 2007
- Published by Elsevier in European Journal of Pharmacology
- Vol. 561 (1-3) , 23-31
S18986: A positive modulator of AMPA-receptors enhances (S)-AMPA-mediated BDNF mRNA and protein expression in rat primary cortical neuronal cultures
- 17 March 2005
- Published by Elsevier in European Journal of Pharmacology
- Vol. 511 (2-3) , 127-136
In vivo neuroprotective effects of the novel imidazolyl nitrone free-radical scavenger (Z)-α-[2-thiazol-2-yl)imidazol-4-yl]-N-tert-butylnitrone (S34176)
- 17 March 2005
- Published by Elsevier in European Journal of Pharmacology
- Vol. 511 (2-3) , 127-136
In vivo neuroprotective effects of the novel imidazolyl nitrone free-radical scavenger (Z)-α-[2-thiazol-2-yl)imidazol-4-yl]-N-tert-butylnitrone (S34176)
- 2 April 2003
- Vol. 57 (6) , 554-63
[In vivo exploration of cerebral ischemia: use of neuroprotective agents in animal studies].
A "good" in vivo animal model of stroke must reproduce the etiology, anatomical, functional and metabolic consequences of human pathology and must also permit the study of anti-ischemic drugs in conditions pertinent to the clinical therapeutics. As stroke is a very heterogeneous clinical entity, such a model could only mimic a limited part of stroke. Animal data are usually collected in healthy laboratory rodents of the same age, in which a standardized amount of cerebral ischemia is induced by a reproducible intervention. In contrast, aetiology, location and severity of ischaemic stroke in patients is very heterogeneous. Among the various animal models of stroke, two of them are particularly used: a model of global transient ischemia by occlusion of the 4-vessels in the rat (Pulsinelli's model), which induces a delayed neuronal death in the hippocampus and model(s) of permanent or transient focal cerebral ischemia occluding the middle cerebral artery in rodents. A large number of compounds have been shown to be active using these two animal models, but unfortunately, none of them were found to be active in clinical trials. Various factors could be responsible for this major discrepancy and some of them are not related to pre-clinical studies, but to the complexities of the clinical problem of stroke. Failure in the translation of results from animals models to humans implicates potential limitations of the current drug development process. Retrospective analysis of studies suggests possible improvements at several stages during pre-clinical studies. Standardized guidelines for preclinical evaluation of neuroprotective drugs may improve chances of success. For example, preclinical studies should be performed in at least 2 species and 2 strains for a specific specie in order to take into account known strain and species differences. Moreover, while neuroprotection drug development is dominated by volumetric histology as the outcome measure, the demonstration of functional benefits must be performed both after short and long periods of recovery. Attempts should be made to use multiple models such as stroke-prone spontaneously hypertensive rats, outbred rodents and aged animals that more closely simulate clinical conditions. In addition, treatment in animals should not be given immediately after ischaemia, but after a delay, as most patients are not treated within minutes of stroke onset. Animal models should be used to determine dosage and duration of therapy, which will vary with the pharmacokinetic properties of different agents. Moreover, complete dose-response curves should be established as bell-shaped dose-responses curves may predict dose-limiting adverse effects that hinder subsequent efficacy trials. Finally, physiological monitoring (cerebral blood flow, blood pressure and gazes, body temperature, glycemia, ...) should be performed to eliminate confounding variables and to observe adverse systemic effects. The future of neuroprotection for stroke remains bright in spite of previous disappointments.
- 2 April 2003
- Vol. 57 (6) , 554-63
[In vivo exploration of cerebral ischemia: use of neuroprotective agents in animal studies].
A "good" in vivo animal model of stroke must reproduce the etiology, anatomical, functional and metabolic consequences of human pathology and must also permit the study of anti-ischemic drugs in conditions pertinent to the clinical therapeutics. As stroke is a very heterogeneous clinical entity, such a model could only mimic a limited part of stroke. Animal data are usually collected in healthy laboratory rodents of the same age, in which a standardized amount of cerebral ischemia is induced by a reproducible intervention. In contrast, aetiology, location and severity of ischaemic stroke in patients is very heterogeneous. Among the various animal models of stroke, two of them are particularly used: a model of global transient ischemia by occlusion of the 4-vessels in the rat (Pulsinelli's model), which induces a delayed neuronal death in the hippocampus and model(s) of permanent or transient focal cerebral ischemia occluding the middle cerebral artery in rodents. A large number of compounds have been shown to be active using these two animal models, but unfortunately, none of them were found to be active in clinical trials. Various factors could be responsible for this major discrepancy and some of them are not related to pre-clinical studies, but to the complexities of the clinical problem of stroke. Failure in the translation of results from animals models to humans implicates potential limitations of the current drug development process. Retrospective analysis of studies suggests possible improvements at several stages during pre-clinical studies. Standardized guidelines for preclinical evaluation of neuroprotective drugs may improve chances of success. For example, preclinical studies should be performed in at least 2 species and 2 strains for a specific specie in order to take into account known strain and species differences. Moreover, while neuroprotection drug development is dominated by volumetric histology as the outcome measure, the demonstration of functional benefits must be performed both after short and long periods of recovery. Attempts should be made to use multiple models such as stroke-prone spontaneously hypertensive rats, outbred rodents and aged animals that more closely simulate clinical conditions. In addition, treatment in animals should not be given immediately after ischaemia, but after a delay, as most patients are not treated within minutes of stroke onset. Animal models should be used to determine dosage and duration of therapy, which will vary with the pharmacokinetic properties of different agents. Moreover, complete dose-response curves should be established as bell-shaped dose-responses curves may predict dose-limiting adverse effects that hinder subsequent efficacy trials. Finally, physiological monitoring (cerebral blood flow, blood pressure and gazes, body temperature, glycemia, ...) should be performed to eliminate confounding variables and to observe adverse systemic effects. The future of neuroprotection for stroke remains bright in spite of previous disappointments.
- 1 January 2003
- Published by Elsevier in Experimental Gerontology
- Vol. 38 (1-2) , 119-128
Cognition enhancing or neuroprotective compounds for the treatment of cognitive disorders: why? when? which?
- 1 January 2003
- Published by Elsevier in Experimental Gerontology
- Vol. 38 (1-2) , 119-128
Cognition enhancing or neuroprotective compounds for the treatment of cognitive disorders: why? when? which?
- 1 March 2001
- Published by Elsevier in European Journal of Pharmacology
- Vol. 416 (1-2) , 59-68
Protective effect of the antioxidant 6-ethoxy-2,2-pentamethylen-1,2-dihydroquinoline (S 33113) in models of cerebral neurodegeneration
- 1 March 2001
- Published by Elsevier in European Journal of Pharmacology
- Vol. 416 (1-2) , 59-68
Protective effect of the antioxidant 6-ethoxy-2,2-pentamethylen-1,2-dihydroquinoline (S 33113) in models of cerebral neurodegeneration